Glenmark Pharmaceuticals’ arm recalls over 25 products in US market

14 Apr 2025 Evaluate

Glenmark Pharmaceuticals’ US-based subsidiary -- Glenmark Pharmaceuticals Inc, USA is recalling over 25 products in the US market due to Current Good Manufacturing Practice (CGMP) deviations. Glenmark Pharmaceuticals Inc is recalling affected lots of medications like Propafenone Hydrochloride extended-release capsules and Solifenacin Succinate Tablets in America.

It is also recalling products like Voriconazole Tablets, Lacosamide Tablets, Frovatriptan Succinate Tablets and Rufinamide Tablets. The company initiated the Class II recall on March 13 this year. As per the USFDA, a Class-II recall is initiated when the use of, or exposure to, a violative product may lead to temporary or medically reversible health consequences, or when the likelihood of serious adverse health outcomes is minimal.

Glenmark Pharmaceuticals is a global research-led pharmaceutical company with presence across Generics, Specialty and OTC business with operations in over 50 countries.

Glenmark Pharma Share Price

1358.90 -62.95 (-4.43%)
25-Apr-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1786.85
Dr. Reddys Lab 1173.55
Cipla 1525.50
Lupin 2018.35
Zydus Lifesciences 859.10
View more..
© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.
×
Please wait your portfolio is updating...